Drug
Dnl747
Dnl747: highest development phase Phase 1, developed by Denali Therapeutics, Sanofi. 2 trial records tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Denali Therapeutics, Sanofi
Trials
| Drug | Phase | Indication |
|---|---|---|
| DNL747 NCT03757351 | Phase 1 | Amyotrophic Lateral Sclerosis |
| DNL747 NCT03757325 | Phase 1 | Alzheimer Disease |
Latest
No recent events.
Follow Dnl747 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.